Summit Therapeutics Inc

For the period ended Dec 31, 2024. Filed Feb 24, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 24, 2025

SMMT$17.83-0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders' Equity

(in thousands, except share data)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Loss · Total Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balance at December 31, 2021	98,039,540	$980	$384,049		$(2,197)		$(299,548)		$83,284
2022 Rights Offering of common stock, net of offering costs of $111	103,092,783	1,031	98,858		—		—		99,889
Issuance of common stock in lieu of interest to related parties	9,720,291	97	7,497		—		—		7,594
Issuance of common stock under stock purchase plans and exercise of stockoptions	238,811	2	397		—		—		399
Stock-based compensation	—	—	11,948		—		—		11,948
Imputed interest expense on promissory note payable to a related party	—	—	2,018		—		—		2,018
Foreign currency translation adjustment	—	—	—		304		—		304
Net loss	—	—	—		—		(78,782)		(78,782)
Balance at December 31, 2022	211,091,425	$2,110	$504,767		$(1,893)		$(378,330)		$126,654
2023 Rights Offering of common stock, net of offering costs of $619	476,190,471	4,762	494,619		—		—		499,381
Issuance of common stock under employee stock purchase plans and exercise of stock options	596,472	7	922		—		—		929
Issuance of common stock in lieu of cash for Akeso upfront payment	10,000,000	100	45,800		—		—		45,900
Private placement of common stock	2,976,190	30	4,970		—		—		5,000
Exercise of warrants	805,495	8	1,195		—		—		1,203
Stock-based compensation	—	—	14,108		—		—		14,108
Unrealized gain on short-term investments	—	—	—		36		—		36
Reclassification of cumulative translation gain (Note 8)	—	—	—		(419)		—		(419)
Foreign currency translation adjustment	—	—	—		(172)		—		(172)
Net loss	—	—	—		—		(614,928)		(614,928)
Balance at December 31, 2023	701,660,053	$7,017	$1,066,381		$(2,448)		$(993,258)		$77,692
Private placement of common stock, net of offering costs of $140	32,574,640	326	434,534		—		—		434,860
Issuance of common stock under stock purchase plans and exercise of stock options and warrants	1,584,218	15	3,319		—		—		3,334
Proceeds from at-the-market offering, net of commissions and offering costs of $1,190	1,807,093	18	43,015		—		—		43,033
Stock-based compensation	—	—	50,981	—		—		50,981
Unrealized gain on short-term investments	—	—	—		100		—		100
Reclassification of unrealized loss on short-term investments to other expense, net	—	—	—		3		—		3
Foreign currency translation adjustment	—	—	—		60		—		60
Net loss	—	—	—		—		(221,315)		(221,315)
Balance at December 31, 2024	737,626,004	$7,376	$1,598,230		$(2,285)		$(1,214,573)		$388,748

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.